| Protein Name | Frizzled class receptor 8 |
| Gene Name | FZD8 |
| Uniprot | Q9H461 (Human); Q61091 (Mouse) |
| Synonym | frizzled 8, seven transmembrane spanning receptor; frizzled family receptor 8; frizzled homolog 8FZ-8; hFZ8; frizzled-8 |
| Background | FZD8 is encoded by the FZD8 gene. FZD8 is a human homologous mouse Frizzled-8, and there is no intron within the FZD8 gene. FZD8 encodes a 694 amino acid polypeptide with a coil-like cysteine-rich domain, seven transmembrane domains and a C-terminal Ser/Thr-X-Val motif. In human FZD family, FZD8 has the highest homology with FZD5. Studies have found that 4.0-kb FZD8 mRNA can be detected in fetal kidney and brain as well as adult kidney, heart, pancreas, and skeletal muscle. The FZD8 gene is mapped to human chromosome 10p11.2 by fluorescence in situ hybridization. In human cancer cell lines, FZD8 is expressed relatively higher in HeLa S3 (cervical cancer) and A549 (lung cancer). |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX266 | NativeExtract™ Human FZD8 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3650K | MemDX™ Membrane Protein Human FZD8 Expressed in vitro E.coli expression system, Full Length of Mature Protein | E.coli cell-free | Full length | Detergent |
| MPX0029K | MemDX™ Membrane Protein Human FZD8 (Frizzled class receptor 8) Expressed in CHO for Antibody Discovery, Partial (25-172aa) | CHO cell | Partial | N/A |
| Please for more products or customization | ||||
A***r: Ideal for structural studies and ligand-binding assays, supporting rigorous reproducibility.
23/Aug/2023
R**e: Received customized FZD8 constructs with optimized solubility tags.
07/Mar/2024
We provide tailored solutions to meet your specific requirements. Please for more services.
FZD8 Editing for Wnt Pathway Reprogramming
Creative Biolabs offers FZD8 editing services for Wnt pathway reprogramming. Gene editing systems enable precise correction of disease-associated FZD8 mutations or transcriptional modulation of its overexpression. For instance, in colorectal cancer models, inactivation of aberrant FZD8 signaling has demonstrated efficacy in suppressing Wnt/β-catenin-driven tumorigenesis by restoring pathway homeostasis. Creative Biolabs' gene-editing optimization services ensure high specificity for FZD8 allele targeting, minimizing off-site effects.
Recombinant AAV Vectors for FZD8 Transgene Delivery
Creative Biolabs offers recombinant AAV vectors development services for FZD8 transgene delivery. Adeno-associated virus (AAV) vectors engineered with tissue-specific promoters facilitate localized delivery of functional FZD8 genes. Preclinical studies in retinal degeneration models show that AAV-mediated FZD8 expression reinstates Wnt-mediated photoreceptor survival, highlighting its potential for degenerative disorders. Creative Biolabs' proprietary AAV capsid libraries enhance tropism for FZD8-expressing tissues, ensuring maximal therapeutic impact.
Creative Biolabs offers comprehensive and innovative services to drive the development of FZD8 cell therapy. Please for more services.
FZD8-Engineered Mesenchymal Stem Cells (MSCs) for Bone Regeneration
Creative Biolabs offers FZD8-engineered MSCs development services. MSCs genetically modified to overexpress FZD8 amplify Wnt signaling, accelerating osteogenic differentiation in fracture repair. In murine osteoporosis models, these cells enhanced trabecular bone density by 40% compared to controls, underscoring their translational potential. Creative Biolabs' stem cell engineering platforms streamline FZD8 transgene integration while preserving pluripotency.
FZD8-Specific CAR-T Constructs for Solid Tumor Targeting
Creative Biolabs offers FZD8-specific CAR-T constructs services for solid tumor targeting. Chimeric antigen receptor (CAR)-T cells targeting FZD8 surface epitopes exhibit potent cytotoxicity against FZD8-positive triple-negative breast cancer cells. Early-phase trials report tumor volume reduction exceeding 60% in xenograft models, with minimal off-tumor activity. Creative Biolabs' CAR-T development services include epitope validation and cytotoxicity profiling to refine target specificity.
From gene editing design to AAV optimization and CAR-T validation, Creative Biolabs delivers end-to-end solutions for FZD8-targeted drug development. to accelerate your preclinical programs with tailored strategies and industry-leading technical support.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.